ABVC BioPharma regains Nasdaq compliance after equity shortfall notice

ABVC BIOPHARMA, INC.

On April 30, 2025, Nasdaq notified ABVC that stockholders' equity of $723,959 as of April 23 failed Listing Rule 5550(b)(1).
On May 5, 2025, Nasdaq confirmed compliance after ABVC's Q1 2025 10-Q showed equity of $7,956,295, closing the matter.
The company avoided delisting by demonstrating equity above the required minimum through its quarterly filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.